The estimated Net Worth of Garen G Bohlin is at least $2.89 Миллион dollars as of 14 May 2024. Mr. Bohlin owns over 28,985 units of Collegium Pharmaceutical Inc stock worth over $2,670,112 and over the last 12 years he sold COLL stock worth over $0. In addition, he makes $217,616 as Independent Director at Collegium Pharmaceutical Inc.
Sign up
Mr. Bohlin COLL stock SEC Form 4 insiders trading
Garen has made over 3 trades of the Collegium Pharmaceutical Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 28,985 units of COLL stock worth $166,084 on 14 May 2024.
The largest trade he's ever made was buying 41,140 units of Collegium Pharmaceutical Inc stock on 12 September 2023 worth over $50,191. On average, Garen trades about 2,059 units every 31 days since 2013. As of 14 May 2024 he still owns at least 73,760 units of Collegium Pharmaceutical Inc stock.
You can see the complete history of Mr. Bohlin stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Garen Bohlin biography
Garen G. Bohlin serves as Independent Director of the Company. Mr. Bohlin has served as a member of our Board since January 2015. Mr. Bohlin has almost 30 years’ experience serving in executive roles at several biotechnology companies, including Constellation Pharmaceuticals, Inc., where he served as an Executive Vice President from January 2010 to his retirement in April 2012. Prior to that, Mr. Bohlin served as Chief Operating Officer at Sirtris Pharmaceuticals, Inc. (“Sirtris”), which was acquired by GlaxoSmithKline plc. Prior to joining Sirtris, Mr. Bohlin served as President and Chief Executive Officer of Syntonix Pharmaceuticals, Inc. (“Syntonix”), which was acquired by Biogen Idec. Prior to Syntonix, Mr. Bohlin spent 14 years in executive management at Genetics Institute, Inc. (“Genetics Institute”), which was acquired by Wyeth. Prior to Mr. Bohlin’s tenure at Genetics Institute, he was a partner at Arthur Andersen & Co., where he spent 13 years. Since his retirement, Mr. Bohlin has served on the boards of directors of several companies. Mr. Bohlin currently serves on the board of directors of Tetraphase Pharmaceuticals, Inc. (NASDAQ: TTPH) (2010 to present) and Karyopharm Therapeutics, Inc. (NASDAQ GS: KPTI) (2013 to present). Previously, he served on the board of directors of Acusphere, Inc. (OTC: ACUS) (2005 to 2015), Proteon Therapeutics, Inc. (NASDAQ: PRTO) (2014 to 2020) and several other publicly traded and privately held biotechnology companies. Mr. Bohlin graduated from the University of Illinois with a B.S. in Accounting and Finance in 1970.
What is the salary of Garen Bohlin?
As the Independent Director of Collegium Pharmaceutical Inc, the total compensation of Garen Bohlin at Collegium Pharmaceutical Inc is $217,616. There are 11 executives at Collegium Pharmaceutical Inc getting paid more, with Joseph Ciaffoni having the highest compensation of $4,032,630.
How old is Garen Bohlin?
Garen Bohlin is 72, he's been the Independent Director of Collegium Pharmaceutical Inc since 2015. There are no older and 18 younger executives at Collegium Pharmaceutical Inc.
What's Garen Bohlin's mailing address?
Garen's mailing address filed with the SEC is C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVENUE, NEWTON, MA, 02459.
Insiders trading at Collegium Pharmaceutical Inc
Over the last 9 years, insiders at Collegium Pharmaceutical Inc have traded over $80,399,308 worth of Collegium Pharmaceutical Inc stock and bought 1,112,375 units worth $13,316,951 . The most active insiders traders include Group Holdings (Sbs) Adviso..., John Gordon Freund и David Hirsch. On average, Collegium Pharmaceutical Inc executives and independent directors trade stock every 35 days with the average trade being worth of $2,130,406. The most recent stock trade was executed by Shirley R. Kuhlmann on 5 September 2024, trading 20,225 units of COLL stock currently worth $773,809.
What does Collegium Pharmaceutical Inc do?
collegium pharmaceutical, inc. is a specialty pharmaceutical company developing and planning to commercialize next generation, abuse-deterrent products for the treatment of patients suffering from chronic pain and other diseases. with a substantial number of patients suffering from chronic pain, collegium is committed to developing and commercializing a portfolio of products that address the growing problems associated with non-medical use, abuse and misuse of prescription products by leveraging the company’s proprietary deterx® technology platform. deterx technology can be used with drugs that are commonly abused such as opioids and amphetamines, as well as drugs that have a narrow therapeutic index that would benefit from protection against misuse such as breaking, crushing, grinding, or dissolving the product. the deterx technology platform is covered by u.s. and international patents and patent applications. collegium’s lead product candidate, xtampza er™, is an abuse-deterrent, ex
What does Collegium Pharmaceutical Inc's logo look like?
Complete history of Mr. Bohlin stock trades at Collegium Pharmaceutical Inc, Karyopharm Therapeutics Inc и Tetraphase Pharmaceuticals
Collegium Pharmaceutical Inc executives and stock owners
Collegium Pharmaceutical Inc executives and other stock owners filed with the SEC include:
-
Joseph Ciaffoni,
President, Chief Executive Officer, Director -
Scott Dreyer,
Executive Vice President, Chief Commercial Officer -
Richard Malamut,
Executive Vice President and Chief Medical Officer -
Paul Brannelly,
Chief Financial Officer, Executive Vice President -
Shirley Kuhlmann,
Executive Vice President, General Counsel, Secretary -
Alison Fleming,
Executive Vice President, Chief Technology Officer -
Joseph J. Ciaffoni,
Pres, CEO & Director -
Shirley R. Kuhlmann,
Exec. VP, Gen. Counsel & Sec. -
Dr. Richard Malamut,
Exec. VP & Chief Medical Officer -
Michael Heffernan,
Chairman of the Board -
Gino Santini,
Lead Independent Director -
Garen Bohlin,
Independent Director -
John Fallon,
Independent Director -
Theodore Schroeder,
Independent Director -
John Freund,
Independent Director -
Gwen Melincoff,
Independent Director -
Michael Thomas Heffernan B.S. Pharm, R.Ph.,
Co-Founder & Chairman -
Michael Thomas Heffernan,
Co-Founder & Chairman -
Rita Balice-Gordon,
Director -
Scott Sudduth,
Head of Technical Operations -
Marlo Manning,
Head of HR -
Scott Dreyer,
Exec. VP & Chief Commercial Officer -
Colleen Tupper,
Exec. VP & CFO -
Jack Maroney,
VP of Sales -
Bart J. Dunn,
Exec. VP of Strategy & Corp. Devel. -
Alex Dasalla,
Head of Investor Relations -
Barry S Duke,
See remarks -
Eran Nadav,
Director -
David Hirsch,
Director -
Yasunori Kaneko,
10% owner -
Venture Partners V Lp Skyli...,
-
Capital Partners, Llc Tamme...,
-
Thomas B Smith,
EVP and Chief Medical Officer -
Colleen Tupper,
EVP & Chief Financial Officer -
Patrick J Heron,
Director -
Capital Partners, Llc Longi...,
-
Healthcare Vi, L.P.Fhm Vi, ...,
-
Group Holdings (Sbs) Adviso...,
-
Venture Partners V Lp Skyli...,
-
Neil F. Mc Farlane,
Director